F2
Prothrombin
As of the edition of 20 October 2026, F2 (prothrombin, UniProt P00734) has 13 drugs tested at it and 29 companies on the list, 2 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00734
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 490
- Disease areas
- Heart and blood vessels; Nervous system; Blood and lymph; Lungs and airways; Inherited and neonatal; Digestive system; Infections; Urinary and reproductive
- Registered trials of its drugs
- 371
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 10 |
| Went quiet | 2 |
| Withdrawn from market | 1 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dabigatran etexilate | Marketed | Phase 4 | Ended 2025 |
| Dabigatran | Marketed | Phase 4 | none listed |
| Bivalirudin | Marketed | Phase 4 | none listed |
| Argatroban | Marketed | Phase 4 | none listed |
| Defibrotide | Marketed | Phase 4 | none listed |
| Antithrombin iii human | Marketed | Phase 4 | Ended 2003 |
| Antithrombin alfa | Marketed | Phase 4 | Ended 2021 |
| Atecegatran metoxil | Went quiet | Phase 2 | none listed |
| Desirudin | Marketed | Phase 4 | Ended 2015 |
| Ichorcumab | Went quiet | Phase 2 | none listed |
| Lepirudin | Marketed | Phase 2 | none listed |
| Ximelagatran | Withdrawn from market | Phase 3 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 9 |
| Engaged | 2 |
| Undetermined | 16 |
| Total on the list | 29 |
| Company | Route |
|---|---|
| Boehringer Ingelheim | Route B |
| Jazz Pharmaceuticals | Route B |
| Bausch Health | Route B |
The other 26 companies at F2
In the product29 companies in all; 26 are not named here, and no score is.
See the 29 companies at F2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.